MA27742A1 - Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose. - Google Patents

Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.

Info

Publication number
MA27742A1
MA27742A1 MA28465A MA28465A MA27742A1 MA 27742 A1 MA27742 A1 MA 27742A1 MA 28465 A MA28465 A MA 28465A MA 28465 A MA28465 A MA 28465A MA 27742 A1 MA27742 A1 MA 27742A1
Authority
MA
Morocco
Prior art keywords
compounds
treatment
phenelazol
ylmethoxy
ppar
Prior art date
Application number
MA28465A
Other languages
English (en)
French (fr)
Inventor
Christian Stapper
Stefanie Keil
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27742A1 publication Critical patent/MA27742A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
MA28465A 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose. MA27742A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA27742A1 true MA27742A1 (fr) 2006-02-01

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Country Status (34)

Country Link
US (5) US7365084B2 (US07259177-20070821-C00088.png)
EP (3) EP1599455B1 (US07259177-20070821-C00088.png)
JP (3) JP2006519193A (US07259177-20070821-C00088.png)
KR (3) KR20050105492A (US07259177-20070821-C00088.png)
CN (3) CN100439347C (US07259177-20070821-C00088.png)
AR (3) AR043432A1 (US07259177-20070821-C00088.png)
AT (3) ATE430738T1 (US07259177-20070821-C00088.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00088.png)
BR (3) BRPI0407907A (US07259177-20070821-C00088.png)
CA (3) CA2517381A1 (US07259177-20070821-C00088.png)
CL (2) CL2004000391A1 (US07259177-20070821-C00088.png)
CO (2) CO5690580A2 (US07259177-20070821-C00088.png)
DE (4) DE10308355A1 (US07259177-20070821-C00088.png)
DK (3) DK1599452T3 (US07259177-20070821-C00088.png)
EC (2) ECSP055986A (US07259177-20070821-C00088.png)
ES (3) ES2329366T3 (US07259177-20070821-C00088.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00088.png)
IL (2) IL170314A (US07259177-20070821-C00088.png)
MA (3) MA27742A1 (US07259177-20070821-C00088.png)
MX (3) MXPA05008988A (US07259177-20070821-C00088.png)
NO (3) NO20054398L (US07259177-20070821-C00088.png)
OA (2) OA13035A (US07259177-20070821-C00088.png)
PA (1) PA8596801A1 (US07259177-20070821-C00088.png)
PE (3) PE20050292A1 (US07259177-20070821-C00088.png)
PL (3) PL378437A1 (US07259177-20070821-C00088.png)
PT (3) PT1599453E (US07259177-20070821-C00088.png)
RS (1) RS20050594A (US07259177-20070821-C00088.png)
RU (3) RU2005129995A (US07259177-20070821-C00088.png)
SA (1) SA04250153A (US07259177-20070821-C00088.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00088.png)
TW (3) TW200500349A (US07259177-20070821-C00088.png)
UY (2) UY28209A1 (US07259177-20070821-C00088.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00088.png)
ZA (2) ZA200505768B (US07259177-20070821-C00088.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006347121B2 (en) 2006-08-10 2013-06-06 Acacia-No-Ki Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
JP5440490B2 (ja) 2008-02-29 2014-03-12 日産化学工業株式会社 チオフェン化合物及びその中間体の製造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184783A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
KR19990077319A (ko) 1996-01-17 1999-10-25 한센 핀 베네드, 안네 제헤르 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용
ATE356830T1 (de) 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PL192664B1 (pl) 1996-12-31 2006-11-30 Reddys Lab Ltd Dr Pochodne azolidynodionu, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne, ich zastosowanie w leczeniu cukrzycy i związanych z nią chorób oraz związki pośrednie
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) * 1998-08-27 2000-03-21 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
CA2378878A1 (en) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
IL148148A0 (en) * 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
ES2215769T3 (es) 1999-12-03 2004-10-16 Astrazeneca Ab Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
KR20080067009A (ko) 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
EA004244B1 (ru) 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
KR100502876B1 (ko) 2000-04-28 2005-07-21 아사히 가세이 파마 가부시키가이샤 신규 이환성 화합물
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
KR20030007934A (ko) * 2000-06-09 2003-01-23 아벤티스 파마 도이칠란트 게엠베하 아실페닐 우레아 유도체, 이의 제조방법 및 약제로서의이의 용도
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US6930120B2 (en) * 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
SK7822003A3 (en) 2000-12-21 2003-12-02 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
EP1726586A1 (en) * 2000-12-25 2006-11-29 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
JP2004529097A (ja) * 2001-02-15 2004-09-24 ファイザー・プロダクツ・インク Pparアゴニスト
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CA2448552A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EP1425014B1 (de) 2001-08-31 2006-12-13 Sanofi-Aventis Deutschland GmbH Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
DE60327922D1 (de) 2002-02-05 2009-07-23 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
TNSN05204A1 (en) 2007-06-11
AU2004215677A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
AR043427A1 (es) 2005-07-27
RU2005129995A (ru) 2006-01-27
ES2287700T3 (es) 2007-12-16
US20080015238A1 (en) 2008-01-17
MXPA05008995A (es) 2005-10-18
TW200508210A (en) 2005-03-01
ZA200505768B (en) 2005-11-23
DK1599453T3 (da) 2009-08-24
BRPI0407907A (pt) 2006-02-14
JP2006519193A (ja) 2006-08-24
TW200510352A (en) 2005-03-16
ATE435217T1 (de) 2009-07-15
TW200500349A (en) 2005-01-01
JP2006519199A (ja) 2006-08-24
EP1599452B1 (de) 2007-06-20
BRPI0407758A (pt) 2006-02-14
AU2004215672A1 (en) 2004-09-10
CN1753881A (zh) 2006-03-29
CO5690578A2 (es) 2006-10-31
PL378130A1 (pl) 2006-03-06
AU2004215673B2 (en) 2009-10-01
AR043432A1 (es) 2005-07-27
AU2004215673A1 (en) 2004-09-10
US7872034B2 (en) 2011-01-18
US7335671B2 (en) 2008-02-26
RS20050594A (en) 2007-12-31
NO20054408D0 (no) 2005-09-22
CN100439345C (zh) 2008-12-03
ATE365159T1 (de) 2007-07-15
PE20050293A1 (es) 2005-05-24
ECSP055985A (es) 2006-01-16
ZA200505765B (en) 2006-05-31
EP1599455B1 (de) 2009-07-01
PL378437A1 (pl) 2006-04-03
DE502004009690D1 (de) 2009-08-13
CA2517386A1 (en) 2004-09-10
JP2006519194A (ja) 2006-08-24
WO2004076428A1 (de) 2004-09-10
KR20050106462A (ko) 2005-11-09
SA04250153A (ar) 2005-12-03
EP1599455A1 (de) 2005-11-30
CN100398526C (zh) 2008-07-02
UY28209A1 (es) 2004-09-30
MXPA05008988A (es) 2005-10-18
AU2004215677B2 (en) 2010-01-07
US20040209920A1 (en) 2004-10-21
CL2004000391A1 (es) 2005-01-07
ES2326418T3 (es) 2009-10-09
US20080167354A1 (en) 2008-07-10
NO20054396D0 (no) 2005-09-22
PT1599452E (pt) 2007-09-12
MA27736A1 (fr) 2006-02-01
DK1599452T3 (da) 2007-10-01
RU2005130002A (ru) 2006-01-27
AR043433A1 (es) 2005-07-27
OA13034A (en) 2006-11-10
PE20050292A1 (es) 2005-05-24
PT1599453E (pt) 2009-07-14
IL170314A (en) 2010-11-30
ES2329366T3 (es) 2009-11-25
US7259177B2 (en) 2007-08-21
AU2004215672B2 (en) 2010-01-07
UY28210A1 (es) 2004-09-30
DK1599455T3 (da) 2009-11-09
WO2004076427A1 (de) 2004-09-10
CN1753879A (zh) 2006-03-29
NO20054396L (no) 2005-11-11
HRP20050742A2 (en) 2006-09-30
EP1599453A1 (de) 2005-11-30
KR20050106461A (ko) 2005-11-09
EP1599453B1 (de) 2009-05-06
PT1599455E (pt) 2009-09-29
BRPI0407814A (pt) 2006-02-14
NO20054398D0 (no) 2005-09-22
CN1756748A (zh) 2006-04-05
CA2517381A1 (en) 2004-09-10
ATE430738T1 (de) 2009-05-15
US20050215596A1 (en) 2005-09-29
DE502004004139D1 (de) 2007-08-02
RU2005129992A (ru) 2006-02-10
CA2516620A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
MA27737A1 (fr) 2006-02-01
ECSP055986A (es) 2006-01-16
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
KR20050105492A (ko) 2005-11-04
PE20040959A1 (es) 2005-01-17
DE502004009453D1 (de) 2009-06-18
EP1599452A1 (de) 2005-11-30
CN100439347C (zh) 2008-12-03
US7365084B2 (en) 2008-04-29
US20050101637A1 (en) 2005-05-12
OA13035A (en) 2006-11-10
HRP20050744A2 (en) 2006-09-30
DE10308355A1 (de) 2004-12-23
NO20054398L (no) 2005-11-02
CL2004000392A1 (es) 2005-04-22
CO5690580A2 (es) 2006-10-31
MXPA05008951A (es) 2005-11-04
TNSN05206A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
MA27742A1 (fr) Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.
MA27741A1 (fr) Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments
MA29804B1 (fr) Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
MA29553B1 (fr) Procedes de production d'acide 4-(biphenylyl) azetidin-2-one phosphoniques
MA27909A1 (fr) Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
WO2008033468A3 (en) Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
MA32120B1 (fr) Nouveaux composes chimiques
BRPI0519769A2 (pt) compostos orgÂnicos
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA31116B1 (fr) Procede de synthese de derives de l'acide 3-amino-tetrahydro-furan-3-carboxylique et utilisation de ceux-ci en tant que medicaments
EP0776881B1 (fr) Composés biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmétiques les contenant et utilisations
MA32108B1 (fr) Derives d'indazole
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
MA27740A1 (fr) Dérivés arylcycloalkylés comportant des chaines latérales ramifiées servant de modulateurs du récepteur PPAR, procédé pour les préparer, et leur utilisation en tant que médicaments
MA27743A1 (fr) Dérivés d'acides alcano??ques à groupe cycloalkyle substitué, procédés de production de ceux-ci, et leur utilisation comme médicament
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
CN104271587A (zh) Hsp90C端抑制剂